Cardiol Therapeutics to present at Sept. 14 NY conference

Cardiol Therapeutics Inc. (CRDL) reported that it will participate in a Fireside Chat at the H.C.

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. (CRDL) reported that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT, with a live webcast available through the Investors section of its website.

The company describes itself as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule drug candidate CardiolRx™, which targets inflammasome pathway activation. Cardiol highlights its MAVERIC Program in recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, for which CardiolRx™ has U.S. FDA Orphan Drug Designation. It also notes the completed Phase II ARCHER study in acute myocarditis and ongoing development of CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure.

Key Figures

Conference presentation time: 10:30 a.m. EDT Conference date: September 14, 2026 Heart failure healthcare costs: US$30 billion per year +4 more

7 metrics

Conference presentation time 10:30 a.m. EDT Time of Cardiol’s Fireside Chat on September 14, 2026, at the H.C. Wainwright conference

Conference date September 14, 2026 Date of Cardiol Therapeutics’ Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Heart failure healthcare costs US$30 billion per year Estimated annual healthcare costs associated with heart failure in the United States cited by Cardiol

Orphan Drug Designation Granted for CardiolRx™ in pericarditis U.S. FDA Orphan Drug Designation for CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis

MAvERIC-Pilot study phase Phase II Completed Phase II MAvERIC-Pilot study in recurrent pericarditis (NCT05494788)

MAVERIC trial phase Phase III Ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis (NCT06708299)

ARCHER study phase Phase II Completed Phase II ARCHER study in acute myocarditis (NCT05180240)

Key Terms

Orphan Drug Designation, recurrent pericarditis, acute myocarditis, inflammasome pathway activation, +2 more

6 terms

Orphan Drug Designation regulatory

"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

recurrent pericarditis medical

"The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis"

Inflammation of the thin sac around the heart that comes back after a first episode. Like a door that keeps sticking shut even after being fixed, recurrent pericarditis involves repeated bouts of chest pain, fever, or fatigue that can require ongoing treatment, tests, or even procedures. Investors track it because recurrent disease affects healthcare spending, drug trial design, regulatory review, and the potential market for therapies aimed at preventing or managing flare-ups.

acute myocarditis medical

"The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis"

Acute myocarditis is a sudden inflammation of the heart muscle that can weaken the heart’s ability to pump and cause irregular rhythms, often requiring medical treatment or hospitalization. For investors, it matters because cases can affect employee or executive health, trigger product safety or clinical-trial concerns, increase medical and legal costs, and prompt regulatory scrutiny—similar to how a jammed pump can slow down an entire factory’s output and raise repair bills.

inflammasome pathway activation medical

"CardiolRx™ modulates inflammasome pathway activation, an intracellular innate immune system"

A cascade in certain immune cells where protein complexes called inflammasomes act like an intracellular alarm system, activating enzymes that produce inflammatory signals (notably IL‑1β and IL‑18) and can trigger a form of cell death. Scientists target or measure this pathway because turning it on or off can drive disease processes, serve as a biomarker of drug effect, or create safety and regulatory considerations for therapies, much like flipping a building’s fire alarm can change how people respond.

forward-looking information regulatory

"This news release contains "forward-looking information" within the meaning of applicable"

Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.

anti-fibrotic therapies medical

"focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart"

FAQ

When will Cardiol Therapeutics (CRDL) present at the H.C. Wainwright conference?

Cardiol Therapeutics will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 10:30 a.m. EDT, at the Lotte New York Palace Hotel in New York, in the Louis Room on the 4th floor.

How can investors access the Cardiol Therapeutics (CRDL) Fireside Chat webcast?

A live webcast of Cardiol’s Fireside Chat will be accessible under “Events & Presentations” in the Investors section of the company’s website at www.cardiolrx.com/investors/events-presentations/.

What is CardiolRx™, Cardiol Therapeutics’ lead drug candidate?

CardiolRx™ is a small-molecule drug candidate that modulates inflammasome pathway activation, an innate immune response linked to inflammation and fibrosis in pericarditis, myocarditis, and heart failure. It is central to Cardiol’s clinical programs in recurrent pericarditis and acute myocarditis.

What is the MAVERIC Program mentioned by Cardiol Therapeutics (CRDL)?

The MAVERIC Program evaluates CardiolRx™ for recurrent pericarditis. It includes a completed Phase II MAvERIC-Pilot study (NCT05494788) and an ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for pericarditis, including recurrent pericarditis.

What was studied in the ARCHER Program at Cardiol Therapeutics?

The ARCHER Program evaluated CardiolRx™ in acute myocarditis, a cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death under age 35. It comprises the completed Phase II ARCHER study (NCT05180240) assessing safety, tolerability, and efficacy.

What is CRD-38 in Cardiol Therapeutics’ pipeline?

CRD-38 is described as a novel, subcutaneously administered drug formulation intended for treating inflammatory heart disease, including heart failure. Cardiol notes that heart failure is a leading cause of death and hospitalization, with U.S. healthcare costs exceeding US$30 billion per year.

Does Cardiol Therapeutics (CRDL) provide any forward-looking statements in this update?

Yes. Cardiol includes forward-looking information regarding its focus on developing anti-inflammatory and anti-fibrotic therapies, its planned clinical studies and timelines, including the plan to complete the Phase III study in recurrent pericarditis, and development plans for CRD-38, subject to various risks and uncertainties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 08:10 AM Accepted by SEC EDGAR 09/09/2026 - 08:10 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated September 9, 2026 - Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: September 9, 2026	By:	/s/ Christopher Waddick
		Christopher Waddick
	Title:	Chief Financial Officer

EXHIBIT 99.1

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

TORONTO, Sept. 9, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT.

H.C. Wainwright 28^th Annual Global Investment Conference

When: Monday, September 14 at 10:30 a.m. EDT.
Where: Lotte New York Palace Hotel, in the Louis Room (4^th Floor)

A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx^™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx^™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx^™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx^™, specifically in acute myocarditis--an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx^™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure--a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx^™; and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-a-fireside-chat-at-the-hc-wainwright-28th-annual-global-investment-conference-302873560.html

SOURCE Cardiol Therapeutics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2026/09/c9492.html

%CIK: 0001702123

For further information: For further information, please contact: Investor.relations@cardiolrx.com

CO: Cardiol Therapeutics Inc.

CNW 07:27e 09-SEP-26

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 NEWS RELEASE DATED SEPTEMBER 9, 2026 8.7 KB